부산대학교 도서관

Dipeptidyl peptidase-4 (DPP-4) inhibitors have been reported to suppress atherosclerosis progression in atherosclerotic mouse models through unclear mechanisms. In this study, we investigated the effect of the DPP-4 inhibitor, linagliptin, on macrophage polarization in vitro and in vivo. Mouse bone marrow macrophages (BMMs) were used in in vitro assays. High fat diet (HFD)-fed Apoe −/− mice were treated orally with linagliptin (10 mg/kg−1•day−1) or a vehicle (water) control. In in vitro assays using BMMs, treatment with LPS and IFNγ decreased the mRNA-expression levels of alternatively activated macrophage (M2) markers, and linagliptin treatment prevented these reductions. The mRNA levels of M2 markers and the number of M2 macrophages in the aorta were higher in linagliptin groups than in control groups. Linagliptin decreased the size of atherosclerotic lesions in HFD-fed Apoe −/− mice. Interestingly, inflammatory stimulation increased DPP-4 expression, and linagliptin suppressed these effects in BMMs. Treatment with DPP-4 small-interfering RNA (siRNA) reproduced linagliptin-mediated alteration of M2 polarization. Linagliptin increased M2 macrophage polarization by inhibiting DPP-4 expression and activity. These findings may indicate the beneficial effects of DPP-4 inhibitors on the progression of diabetic macrovascular complications. Image 1 • Linagliptin increased M2 macrophage abundances and M2 marker expression. • Linagliptin decreased the size of atherosclerotic lesions in HFD-fed Apoe −/− mice. • Inflammation increased DPP-4 expression, which was blocked by linagliptin in BMMs. • Treatment with DPP-4 siRNA reproduced linagliptin-induced M2 polarization. • DPP-4 inhibitors may slow the progression of diabetic macrovascular complications. [ABSTRACT FROM AUTHOR]